butabarbital decreases effects of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of CYP3A4 inducers could decrease sufentanil ranges and efficacy, maybe precipitating withdrawal syndrome in people that have developed Actual physical dependence to sufentanil. Discontinuation